Virpax Pharmaceuticals (VRPX) Stock Forecast, Price Target & Predictions


OverviewOwnershipFinancialsChart

VRPX Stock Forecast


Virpax Pharmaceuticals stock forecast is as follows: an average price target of $3.00 (represents a 809.09% upside from VRPX’s last price of $0.33) and

VRPX Price Target


Virpax Pharmaceuticals Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 19, 2024Naz RahmanMaxim Group$3.00$1.7076.47%809.09%

The latest Virpax Pharmaceuticals stock forecast, released on Jul 19, 2024 by Naz Rahman from Maxim Group, set a price target of $3.00, which represents a 76.47% increase from the stock price at the time of the forecast ($1.70), and a 809.09% increase from VRPX last price ($0.33).

Virpax Pharmaceuticals Price Target by Period


1M3M12M
# Anlaysts--1
Avg Price Target--$3.00
Last Closing Price$0.33$0.33$0.33
Upside/Downside-100.00%-100.00%809.09%

In the current month, the average price target of Virpax Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Virpax Pharmaceuticals's last price of $0.33. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Virpax Pharmaceuticals Financial Forecast


Virpax Pharmaceuticals Revenue Forecast

Dec 24Sep 24Jun 24
Revenue---
Avg Forecast---
High Forecast---
Low Forecast---
# Analysts---
Surprise %---

Virpax Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. VRPX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Virpax Pharmaceuticals EBITDA Forecast

Dec 24Sep 24Jun 24
# Analysts---
EBITDA---
Avg Forecast---
High Forecast---
Low Forecast---
Surprise %---

undefined analysts predict VRPX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Virpax Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Virpax Pharmaceuticals Net Income Forecast

Dec 24Sep 24Jun 24
# Analysts---
Net Income---
Avg Forecast$-1.26M$-2.52M$-3.02M
High Forecast$-1.26M$-2.52M$-3.02M
Low Forecast$-1.26M$-2.52M$-3.02M
Surprise %---

Virpax Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VRPX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Virpax Pharmaceuticals SG&A Forecast

Dec 24Sep 24Jun 24
# Analysts---
SG&A---
Avg Forecast---
High Forecast---
Low Forecast---
Surprise %---

Virpax Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to VRPX last annual SG&A of $NaN (undefined).

Virpax Pharmaceuticals EPS Forecast

Dec 24Sep 24Jun 24
# Analysts---
EPS---
Avg Forecast$-0.27$-0.54$-1.53
High Forecast$-0.27$-0.54$-1.53
Low Forecast$-0.27$-0.54$-1.53
Surprise %---

According to undefined Wall Street analysts, Virpax Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VRPX previous annual EPS of $NaN (undefined).

Virpax Pharmaceuticals Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
KPRXKiora Pharmaceuticals$3.49$120.003338.40%Buy
VRPXVirpax Pharmaceuticals$0.34$3.00782.35%
LGVNLongeveron$1.78$10.00461.80%Buy
PRAXPraxis Precision Medicines$73.01$73.771.04%Buy
PALIPalisade Bio$1.90$1.50-21.05%Buy

VRPX Forecast FAQ


Will Virpax Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for VRPX stock, the company can go up by 809.09% (from the last price of $0.33 to the average price target of $3), up by 809.09% based on the highest stock price target, and up by 809.09% based on the lowest stock price target.

Can Virpax Pharmaceuticals stock reach $0?

VRPX's average twelve months analyst stock price target of $3 supports the claim that Virpax Pharmaceuticals can reach $0 in the near future.

What are Virpax Pharmaceuticals's analysts' financial forecasts?

VRPX's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-6.798M (high $-6.798M, low $-6.798M), average SG&A $0 (high $0, low $0), and average EPS is $-2.34 (high $-2.34, low $-2.34).